Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis

International Journal of Cancer

Volumn 78, Issue 5, 1998, Pages 629-635

  Heppner Goss, Kathleen J ^a,c   Brown, Peter D ^b   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; INTESTINE CANCER; INTESTINE TUMOR; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; INTESTINAL NEOPLASMS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENYLALANINE; PROTEASE INHIBITORS; RATS; THIOPHENES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0000278421     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981123)78:5<629::AID-IJC17>3.0.CO;2-8     Document Type: Article

References (35)

1. BALMAIN, A., KRUMLAUF, R., VASS, J.K. and BIRNIE, G.D., Cloning and characterisation of the abundant cytoplasmic 7S RNA from mouse cells. Nucl. Acids Res., 10, 4259-4277 (1982).
2. BERTAUX, B., HORNEBECK, W., EISEN, A.Z. and DUBERTRET, L., Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J. Invest. Dermatol., 97, 679-685 (1991).
3. CHAMBERS, A.F. and MATRISIAN, L.M., Changing views of the role of matrix metalloproteinases in metastasis. J. nat. Cancer Inst., 89, 1260-1270 (1997).
4. CHESLER, L., GOLDE, D.W., BERSCH, N. and JOHNSON, M.D., Metalloproteinase inhibition and erythroid are independent activities of tissue inhibitor of metalloproteinases-1. Blood, 86, 4506-4515 (1995).
5. CORCORAN, M.L. and STETLER-STEVENSON, W.G., Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via cAMP-dependent mechanism. J. biol. Chem., 270, 13453-13459 (1995).
6. DAVIES, B., BROWN, P.D., EAST, N., CRIMMIN, M.J. and BALKWILL, F.R., A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 53, 2087-2091 (1993).
7. DECLERGK, Y.A., HAMMANI, K., KOHN, D. and IMREN, S., Tissue inhibitors of matrix metalloproteinases in tumor growth [Abstract]. American Association of Cancer Research Special Conference. Proteases and Protease Inhibitors (1996).
8. DENHARDT, D.T., On the paradoxical ability of TIMPs either to inhibit or to promote the development and progression of the malignant phenotype. In: S.P. Hawkes, D.R. Edwards and R. Khokha (eds.), Inhibitors of metalloproteinases in development and disease. Harwood Academic Publisher, Lausanne. (1998). (In press.)
9. DOCHERTY, A.J., LYONS, A., SMITH, B.J., WRIGHT, E.M., STEPHENS, P.E., HARRIS, T., MURPHY, G. and REYNOLDS, J.J., Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (Lond.), 315, 761-768 (1985).
10. EDWARDS, D., WATERHOUSE, P., HOLMAN, M. and DENHARDT, D., A growth-responsive gene (16C8) in normal mouse fibroblasts homologous to a human collagenase inhibitor with erythroid-potentiating activity: evidence for constitutive and inducible transcripts. Nucl. Acids Res., 14, 8863-8878 (1986).
11. GASSON, J.C., and 11 OTHERS, Molecular characterization and expression of the gene encode human erythroid-potentiating activity. Nature (Lond.), 315, 768-771 (1985).
12. GUILLEM, J.G., LEVY, M.F., HSIEH, L.L., JOHNSON, M.D., LOGERFO, P. FORDE, K.A. and WEINSTEIN, I.B., Increased levels of phorbin, c-myc, and ornithine decarboxylase RNAs in human colon cancer. Mol. Carcinogenesis, 3, 68-74 (1990).
13. HAYAKAWA, T., YAMASHITA, K., OHUCHI, E. and SHINAGAWA, A., Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci., 107, 2373-2379 (1994).
14. KENNEDY, A.R., BEAZER-BARCLAY, Y., KINZLER, K.W. and NEWBERNE, P.M., Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res., 56, 679-682 (1996).
15. KIM, S.H., ROTH, K.A., MOSER, A.R. and GORDON, J.I., Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia. J. Cell Biol., 123, 877-893 (1992).
16. LUONGO, C., MOSER, A.R., GLEDHTLL, S. and DOVE, W.F., Loss of Apc+ in intestinal tumors from min mice. Cancer Res., 54, 5947-5952 (1995).
17. MARTIN, D.C., RUTHER, N., SANCHEZ-SWEATMAN, O.H., ORR, F.W. and KHOKHA, R., Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene, 13, 569-576 (1996).
18. MATRISIAN, L.M., LEROY, P., RUHLMANN, C., GESNEL, M.-C. and BREATHNACH, R., Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rat fibroblasts. Mol. cell. Biol., 6, 1679-1686 (1986).
19. MOSER, A.R., DOVE, W.F., ROTH, K.A. and GORDON, J.I., The Min (multiple intestinal neoplasia) mutation: Its effect on gut epithelial cell differentiation and interaction with a modifier system. J. Cell Biol., 116, 1517-1526 (1992).
20. MOSER, A.R., PITOT, H.C. and DOVE, W.F., A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322-324 (1990).
21. NEMETH, J.A., RAPE, A., STEINER, M. and GOOLSBY, C.L., TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp. Cell Res., 224, 110-115 (1996).
22. NEWELL, K.J., WITTY, J.P., RODGERS, W.H. and MATRISIAN, L.M., Expression and localization of matrix-degrading metalloproteinases during colorectal turmorigenesis. Mol. Carcinogenesis, 10, 199-206 (1994).
23. SIMON, T.C., ROTH, K.A. and GORDON, J.I., Use of transgenic mice to map cis-acting elements in the liver fatty acid-binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spatial patterns of expression in the gut epithelium and in the liver acinus. J. biol. Chem., 268, 18345-18358 (1993).
24. SOLOWAY, P.D., ALEXANDER, C.M., WERB, Z. and JAENISCH, R., Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. Oncogene, 13, 2307-2314 (1996).
25. STETLER-STEVENSON, W.G., BERSCH, N. and GOLDE, D.W., Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett., 296, 231-234 (1992).
26. STRICKLIN, G.P. and NANNEY, L.B., Immunolocalization of collagenase and TIMP in healing human burn wounds. J. invest. Dermatol., 103, 488-492 (1994).
27. SU, L.K., KINZLER, K.W., VOGELSTEIN, B., PREISINGER, A.C., MOSER, A.R., LUONGO, C., GOULD, K.A. and DOVE, W.F., Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science, 256, 668-670 (1992).
28. SUN, Y., KIM, H., PARKER, M., STETLER-STEVENSON, W.G. and COLBURN, N.H., Lack of suppression of tumor cell phenotype by overexpression of TIMP-3 in mouse JB6 tumor cells: identification of a transfectant with increased tumorigenicity and invasiveness. Anticancer Res., 16, 1-7 (1996).
29. SWEETSER, D., HAUFT, S., HOPPE, P., BIRKENMEIER, E. and GORDON, J., Transgenic mice containing intestinal fatty acid-binding protein-human growth hormone fusion genes exhibit correct regional and cell-specific expression of the reporter gene in their small intestine. Proc. nat. Acad. Sci. (Wash.), 85, 9611-9615 (1988).
30. TAKEUCHI, N., ICHIKAWA, Y., ICHIKAWA, I., MOMIYAMA, N., HASEGAWA, S., NAGASHIMA, Y., MIYAZAKI, K., KOSHIKAWA, N., MITSUHASHI, M. and SHIRMADA, H., Matrilysin gene expression in sporadic and familial colorectal adenomas. Mol. Carcinogenesis, 19, 225-229 (1997).
31. TARABOLETTI, G., GAROFALO, A., BELOTTI, D., DRUDIS, T., BORSOTTI, P., SCANZIANI, E., BROWN, P.D. and GIAVAZZI, R., Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. nat. Cancer Inst., 87, 293-298 (1995).
32. WATSON, S.A., MORRIS, T.M., ROBINSON, G., CRIMMIN, M.J., BROWN, P.D. and HARDCASTLE, J.D., Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res., 55, 3629-3633 (1995).
33. WILSON, C.L., HEPPNER, K.J., LABOSKY, P.A., HOGAN, B.L.M. and MATRISIAN, L.M., Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. nat. Acad. Sci. (Wash.), 94, 1402-1407 (1997).
34. WILSON, C.L., HEPPNER, K.J., RUDOLPH, L.A. and MATRISIAN, L.M., The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol. Biol. Cell, 6, 851-869 (1995).
35. WITTY, J.P., MCDONNELL, S., NEWELL, K., CANNON, P., NAVRE, M., TRESSLER, R.J. and MATRISIAN, L.M., Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res., 54, 4805-4812 (1994).